PYXS Nasdaq

Pyxis Oncology Inc

PYXS | $4.155 -8.28% -9.03% 670K

(0.0% 1d) (-16.1% 1m) (25.7% 1y) (0.0% 2d) (-13.9% 3d) (-12.2% 7d) (14.2% volume)
Earnings Calendar: 2023-11-01
Market Cap: $ 241,544,173
https://pyxisoncology.com
Sec Filling | Patents | 2021 employees

Pyxis Oncology, Inc. is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. Pyxis develops its product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since its launch in 2019, Pyxis has developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that it is developing as monotherapies and in combination with other therapies.

cancer t-cell

add to watch list Paper trade email alert is off

Press-releases

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-03-28 (Crawled : 21:00) - globenewswire.com
PYXS | $4.155 -8.28% -9.03% 670K

Professional, Scientific, and T...

| Email alert Add to watchlist
nasdaq grants

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
Published: 2024-03-21 (Crawled : 12:00) - globenewswire.com
PYXS | $4.155 -8.28% -9.03% 670K

Professional, Scientific, and T...

| -23.39% | O: -7.92% H: 4.0% C: -0.8%
year update financial results

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
Published: 2024-03-13 (Crawled : 12:00) - globenewswire.com
PYXS | $4.155 -8.28% -9.03% 670K

Professional, Scientific, and T...

| -27.02% | O: -1.23% H: 9.06% C: -4.97%

Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
Published: 2024-03-07 (Crawled : 22:00) - globenewswire.com
PYXS | $4.155 -8.28% -9.03% 670K

Professional, Scientific, and T...

| -33.23% | O: -0.48% H: 1.13% C: -9.19%
conference biopharma global

Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting
Published: 2024-03-05 (Crawled : 22:00) - globenewswire.com
PYXS | $4.155 -8.28% -9.03% 670K

Professional, Scientific, and T...

| -35.5% | O: 0.0% H: 3.57% C: -2.64%
pyx-201 pyx-106 preclinical meeting

Pyxis Oncology Announces $50 Million Private Placement
Published: 2024-02-27 (Crawled : 13:00) - globenewswire.com
PYXS | $4.155 -8.28% -9.03% 670K

Professional, Scientific, and T...

| -12.97% | O: 23.01% H: 16.5% C: 8.33%
million

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-12-29 (Crawled : 22:00) - globenewswire.com
PYXS | $4.155 -8.28% -9.03% 670K

Professional, Scientific, and T...

| Email alert Add to watchlist
nasdaq grants